GLP-1 & Weight Loss Clinics
Fast-growing sector under significant regulatory scrutiny. Prescribing requires proper structure.
GLP-1 agonist medications (semaglutide, tirzepatide) have driven explosive growth in weight loss clinic businesses. This growth has attracted significant regulatory attention. Prescribing weight loss medications requires a licensed physician entity and, in CPOM states, a physician-owned PC. The pace of growth in this sector has outpaced compliance infrastructure at many operators.
Key CPOM Considerations
- GLP-1 prescribing (Ozempic, Wegovy, Mounjaro, Zepbound) requires physician oversight
- Compounded GLP-1 prescribing through pharmacies requires physician entity and prescription
- State medical boards are actively investigating weight loss clinic compliance
- FDA has sent warning letters to non-compliant compounding operations
- CPOM applies to any entity that orders or prescribes GLP-1 medications
- Direct-to-consumer GLP-1 platforms face both CPOM and clinical compliance scrutiny
GLP-1 & Weight Loss Clinics — CPOM & Compliance Guide
The GLP-1 Regulatory Landscape
The GLP-1 weight loss market grew from near-zero to billions of dollars in revenue in just a few years. The regulatory response has been correspondingly intense. State medical boards, the FDA, and the FTC have all been active in this space. For CPOM purposes, the key issue is that any entity that employs physicians to prescribe GLP-1 medications or that provides the infrastructure for those prescriptions must be properly structured under state law.
Compounding and Telehealth GLP-1
Many GLP-1 weight loss platforms operate through telehealth and rely on compounding pharmacies for semaglutide or tirzepatide supply. The telehealth CPOM rules apply here — the prescribing platform must have a compliant physician entity in each state where patients are located. Additionally, FDA's enforcement against compounding of GLP-1 medications has directly affected the business models of platforms that relied on compounded supply.
CPOM Structure for Weight Loss Clinics
A GLP-1 weight loss platform operating in CPOM states needs the MSO-PC structure with state-specific physician PCs. The platform (MSO) provides the technology, patient acquisition, and operational infrastructure. The physician PCs in each state provide the medical services — including physician oversight, clinical protocols, and prescription authority. The MSA must preserve physician clinical independence.
The Rubber-Stamp Problem
A significant compliance issue in the GLP-1 space is the 'rubber-stamp prescriber' model — where a physician nominally reviews and approves prescriptions but has no meaningful clinical relationship with the patient. State medical boards and the DEA (where controlled substances are involved) have taken action against this model. CPOM compliance is necessary but so is actual clinical compliance: appropriate physician-patient relationship, medical history review, and clinical judgment.
Multi-State Considerations
Most GLP-1 platforms operate nationally or in multiple states. Each state where patients receive prescriptions is a state where CPOM compliance is required. A national GLP-1 platform without state-specific physician PCs in all operating states has a significant compliance gap.
Key States for GLP-1 & Weight Loss Clinics Operators
These are the states with the highest CPOM enforcement relevance for glp-1 & weight loss clinics businesses:
Disclaimer: This page provides general educational information and does not constitute legal advice. CPOM rules vary by state and evolve over time. Consult a qualified healthcare attorney for advice specific to your situation.
Other Specialty Guides
Structure Your GLP-1 & Weight Loss Clinics Business Compliantly
Submit an interest form for a free consultation specific to your business type and operating states.
Submit Interest Form